Berapa harga TMS Co., Ltd. (4891)

Harga TMS Co., Ltd. (4891) adalah $0.73072946

Apa kapitalisasi pasar TMS Co., Ltd. (4891)

Kapitalisasi pasar TMS Co., Ltd. (4891) adalah $33.30M

Pendapatan TMS Co., Ltd. (4891)

Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceuticals, quasi-drugs, drug substances, medical devices, and various medical commodities. The company's pipeline includes TMS-007, an SMTP congener demonstrating both prothrombolytic and anti-inflammatory/antioxidative activities, which has advanced through Phase 2a clinical trials for the treatment of acute ischemic stroke. Additionally, TMS-008, another SMTP congener with anti-inflammatory/antioxidative properties, is undergoing nonclinical development for addressing inflammatory complications like acute kidney injury and cancer cachexia. A third product candidate, TMS-009, is currently in preclinical development. TMS Co., Ltd. collaborates with Hokkaido University and Kanazawa University to assess the potential of its drug candidates, has a joint research agreement with Teikyo University to identify renal function biomarkers, and maintains a strategic alliance with Ji Xing Pharmaceuticals Limited.

Tahun	Pendapatan	Mengubah
Tidak cukup data untuk tanggal yang disediakan.

Tahun

Pendapatan

Mengubah

Tidak cukup data untuk tanggal yang disediakan.

Perusahaan	Pendapatan	Perbedaan Pendapatan	Negara
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Moderna, Inc. MRNA.US	$2.23B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
CSL Limited CSL.AX	$15.70B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Perusahaan

Pendapatan

Perbedaan Pendapatan

Negara